Page 113 - MemoriaES-Eng

www.ciberes.org

• A A, A Ji, g-A J, M d, u S, P e. Construction,
Most relevant rBueSguiloonZAloSenSioArinoVArAngAuenteS
characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tu-
scientific
berculosis-based vaccine to enter clinical trials.Vaccine. 2013 Oct 1;31(42):4867-73.
articles
• Aguilo Ji, AlonSo H, urAngA S, MArinoVA d, ArBuéS A, de MArtino A. ESX-1-induced apop-
tosis is involved in cell-to-cell spread of Mycobacterium tuberculosis.Cell Microbiol.

2013 Dec;15(12):1994-2005.

• MArinoVA d, gonZAlo-ASenSio J, Aguilo n, MArtín c. Recent developments in tuberculo-
sis vaccines.Expert Rev Vaccines. 2013 Dec;12(12):1431-48.

• r l, V c, B r, V M, A JA. Role of the Mmr efflux pump in
odrigueSillellASAiloiVeiroSínSA
drug resistance in Mycobacterium tuberculosis.Antimicrob Agents Chemother. 2013
Feb;57(2):751-7.

• A H, S S, M c, o i. Mapping IS6110 in high-copy number Mycobac-
lonSoAMPerArtíntAl
terium tuberculosis strains shows specific insertion points in the Beijing genotype.

BMC Genomics. 2013 Jun 25;14:422.

í

Highlights
CLINICAL TRIAL VACCINE MTBVAC: MTBVAC is developed by the University of Za-
ragoza and produced by Biofabri in Spain. MTBVAC received approval by Swiss

Rgulatory Authorities to enter first-in-human Phase 1a clinical trial for safety and

immunogenicity in healthy adults in Lausanne, Switzerland (http://clinicaltrials.
gov/ct2/show/NCT02013245).
é
INTERNATIONALIZATION EUROPEAN PROJECT. In the line Molecular Bases of the

Resistance of mycobacteria Nareb - Nanotherapeutics for antibiotic resistant emer-

ging bacterial pathogens for the application of nanotechnology for therapeutic pur-
poses against emerging pathogens resistant to drugs.

RESULTS TRANSFER INTERNATIONAL. In the line Molecular Epidemiology of Tuber-

culosis & Transposition and Latency of M. tuberculosis. Our groups is collaborator
of European Centre for Disease Prevention and Control (ECDC) and member of the

European network of reference laboratories for tuberculosis since 2009. ERLN-TB

and the new network ERLTB-Net (GRANT/2013/003)

RESULTS TRANSFER. In the line Construction of New Vaccines against Tuberculosis.
Our group has the Spanish Biopharmaceutical BIOFABRI as partner of the Univer-

sity of Zaragoza for the production and development of vaccine against tuberculo-

sis MTBVAC. Transfer agreements with Spanish company funded research funds in
recent years have been: Vacuna Inactivada contra la tuberculosis en base a una

cepa modificada genticamente” INNPACTO IPT-2012-0327-090000 Ministerio de
Economa y Competitividad. 2012-2015.

RESULTS TRANSFER. In the line Molecular Bases of the Resistance of mycobacteria,

technological impact of its activity has resulted in a series of contracts with compa-
13
nies and institutions: GlaxoSmithKline (GSK) in the testing of new compounds with 20
potential anti-tuberculosis activity.
T
OR
P
RE
L
A
NU
N
A
S /
E
ER
B
CI

113